A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · May 2025 · 1 min read
In brief
In brief
Phase 1/2 trial evaluating lenvatinib combined with everolimus in children and young adults with recurrent solid tumors. The combination demonstrated manageable toxicity at 11 mg/m² lenvatinib plus 3 mg/m² everolimus, with limited objective responses but some prolonged disease control in Ewing sarcoma patients.
Written by the GCMD Library team from the article.
Statements in this article
Patients aged 2-21 years with select recurrent or refractory solid tumors were eligible for enrollment.
Phase 2 enrollment was limited to patients with Ewing sarcoma, rhabdomyosarcoma, or high-grade glioma who had received no more than 2 prior VEGF/VEGFR-targeted therapies.
The recommended Phase 2 dose was lenvatinib 11 mg/m2 combined with everolimus 3 mg/m2 orally once daily.
Dose-limiting toxicities at the 11 mg/m2 lenvatinib dose level included proteinuria in one patient and hypertriglyceridemia with hypercholesterolemia in one patient, occurring in 2 of 12 patients treated.
Two patients with rhabdomyosarcoma experienced partial response by Week 16.
Two patients with Ewing sarcoma experienced prolonged disease control lasting at least 23 weeks.
No objective responses were observed in patients with Ewing sarcoma or high-grade glioma by Week 16.
The safety profile in pediatric and young adult patients was similar to that observed in adults with renal cell carcinoma treated with this combination.